Single cell multi-omics company to eradicate cancer

Harbour BioMed is a global, clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in the areas of oncology and immunological diseases to address unmet patient’s needs.

Our mission is very simple: to use immunology to save the lives of the most vulnerable. Whether it’s the young who have yet to develop strong immune systems, the elderly who suffer from waning immune systems, or the immunocompromised whose immune systems are insufficient do to acquired medical conditions or the treatments thereof, Ansun’s mission is to discover and use novel approaches to develop therapies that prevent, treat, and cure some of the world’s most vexing human diseases. This has been our mission since 2003, when Ansun was formed for the purpose of developing a novel approach to treat otherwise untreatable pandemic flu strains (in fact, all flu strains), and it remains our mission today.

see company website

Pharma and diagnostics

PepLib is rethinking peptide drug discovery: a revolutionary platform technology company with a proprietary peptide library, unique screening capabilities, and robust internal drug development programs. PepLib’s novel peptide technology platform uses cyclic peptides to encode and compress half of a billion sequences, including complete peptide libraries up to pentapeptides (ZSenithFive™). PepLib’s platform, powered by Peptide Information Compression Technology (PICT), is capable of high-sensitivity and high-specificity drug mining for a broad spectrum of targets, including membrane-proteins. Intelligently designed, individually isolated and packed peptides in HTS well format support functional assays, including cell-based assay and in vivo assay. PepLib has validated the efficiency of the platform on the well-studied PD-1/PD-L1 model and through their partnerships with multiple pharmaceutical companies and internal development programs in oncology, pain, metabolic disorders, and antimicrobials/antivirals, including COVID. Formed by leading scientists in peptide chemistry and biosynthesis with a combined 75 years of biopharmaceutical R&D experience, PepLib hopes to leverage its innovative platform to advance peptide drug discovery for the global biopharmaceutical community.

We are leaders in therapeutic target discovery and RNA-targeted therapies in Cardiovascular Disease (CVD). Our technology platforms seamlessly integrate synergistically to accelerate development of therapies to treat illnesses where no other treatments have proven effective or ever existed.
We have developed a rich pipeline of therapeutics, including RNAi and NCE's for heart failure, cardiotoxicity, cardiac regeneration and rare cardiometabolic disease.